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Abstract
BACKGROUND: Coronavirus disease-19 (COVID-19) is the first pandemic infectious disease caused by a novel 
coronavirus. Viral pneumonia is a severe complication of COVID-19.
AIM: Due to the high prevalence of this disease globally, especially in Iran, the aim of this study was to determine the 
clinical features of seven patients with probable COVID-19 infected pneumonia in Rasht, North Iran.
MATERIALS AND METHODS: In this retrospective case series study, we described the clinical, laboratory, and 
radiological features of seven patients with probable COVID-19 infected pneumonia at Razi Hospital, Rasht, north of 
Iran, from February 27 to March 16, 2020.
RESULTS: In this study, the most common clinical symptoms during hospitalization in patients with COVID-19 were 
poor appetite (seven cases), dehydration (seven cases), cough (six cases), dyspnea (six cases), fatigue (six cases), 
fever above 38°C (five cases), myalgia (five cases), Chills (five cases), feeling fever (five cases), sore throat (five 
cases), and nausea (five cases), respectively. The average body temperature in these patients was 39.32°C. In 
laboratory findings, erythrocyte sedimentation rate was elevated in three patients. Contrary to most of the evidence, 
C-reactive protein was not elevated in five patients. All patients received antibiotic and antiviral medications and 
received symptomatic treatment. Finally, four patients responded to the treatments and were discharged from the 
hospital; two patients were still hospitalized and only one patient died.
CONCLUSION: Patients with COVID-19 associated pneumonia can be treated by evaluating and implementing 
appropriate therapeutic management. However, at the moment the disease progression for patients with COVID-19 
cannot be accurately predicted.
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Introduction
Concerns have been raised about a new 
outbreak in the world since December 8, 2019, in Wuhan, 
Hubei Province, China, following reports of pneumonia 
with unknown etiology. These patients mostly lived or 
worked in the wholesale markets of Huawei seafood 
(the buying and selling of live animals) [1], [2]. Following 
the identification of the new coronavirus by the 
Chinese Centers for Disease Control and Prevention 
(China CDC), the disease has named Coronavirus 
Disease 2019 by the World Health Organization 
(WHO) [3], [4], [5]. Since January 2020, the spread of 
the disease has increased first in China and then in 
other countries [3] and by February 10, 2020, a total of 
40,261 cases have been diagnosed in China, with 909 
deaths [1], [6]. The disease is transmitted from person 
to person [4] and according to the latest WHO report, 
COVID-19 affected up to 179,111 individuals globally by 
March 17, 2020, of which 7426 people have died [7]. 
The Iranian Ministry of Health and Medical Education 
also reported 14,991 cases of COVID-19 in Iran by 
March 17, 2020, of which 853 cases have died [8].
According to the previous studies, symptoms 
such as fever, cough, myalgia, fatigue, diarrhea, 
shortness of breath, lymphopenia, and lung parenchymal 
opacity were detected in COVID-19 patients [9], [10]. 
The disease was associated with serious complications 
including acute respiratory distress syndrome 
(ARDS), shock, acute cardiac, and kidney injury and 
consequently, death. Clinically, patients with COVID-
19 develop rapidly and eventually severe respiratory 
failure [1]. Epidemiological studies indicated that the 
overall risk of mortality in affected critically ill patients is 
high. Older age, male sex, history of immunodeficiency 
disorders, smoking, and underlying diseases are major 
risk factors for developing severe symptoms of COVID-
19 [11], [12]. However, we have little information on 
clinical features in patients with OVID-19 infected 
pneumonia.
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Due to the high prevalence of COVID-19 
and lack of sufficient details regarding underlying 
mechanism of disease, and its clinical presentation or 
treatment in these patients, the aim of this study was 
to determine the clinical features of seven cases with 
probable COVID-19 infected pneumonia to take a step 
to discover the unknowns of the disease caused by 
SARS-CoV-2.
Case Presentation
This study aimed to determine the clinical 
features of patients with COVID-19 infected pneumonia 
since February 27 to March 16, 2020, on seven cases 
referred to Razi Hospital in Rasht, Guilan Province, 
Iran. This hospital is the main center for the treatment of 
COVID-19 patients in Rasht. In this study, patients with 
suspected diagnosis of COVID-19 infected pneumonia 
were examined through clinical and radiological findings. 
Due to restricted access to reverse transcription 
polymerase chain reaction (RT-PCR) laboratory kits, in 
this study, the diagnosis of COVID-19 pneumonia was 
based on the results of chest computed tomography 
(CT) scan imaging findings, according to the criteria 
developed by Iranian Radiologic Consultant Group [13].
We extracted information from patient records 
and interviews using pre-designed researcher-made 
checklist. This checklist includes demographic and 
clinical characteristics including age, sex, occupation, 
residency location, underlying disease history, history 
of immunosuppressive illness, history of contact to 
COVID-19 patient, history of travel to the China, disease 
symptoms, radiological findings, and factors associated 
with the disease. Consent form was filled out by all of 
the patients, or their family member, anonymously to 
use their medical records, and treatment plan.
In this case series, seven patients with COVID-
19 pneumonia referred to the Razi Hospital in Rasht, 
Iran, were studied since February 27, 2010, to March 
16, 2020. After early diagnosis, treatment and follow-up 
were performed for them. To protect patients’ privacy, 
only purpose-related data were reported. There was 
no material or spiritual burden on the patients and their 
companions.
Case 1
The patient was a 79-year-old housewife. She 
was complaining about cough, loss of appetite and 
fatigue, which led her to the hospital. She had a history 
of hypertension and cardiovascular disease. She was 
under treatment with metoprolol and losartan. She did 
not have a history of travel or contact with a confirmed 
COVID-19 patient. The vital signs of the patient were 
BP =160/90, T = 37.3, SPO2 = 84%, HR =90, and RR =18. 
Oxygen therapy was performed immediately with mask 
(8L/min). Chest x-ray (CXR) and CT scan findings 
have showed bilateral pneumonia. Laboratory findings 
showed that patient alkaline phosphatase (336 U/L) were 
in high range. The patient treatments were symptomatic 
and included with antibiotic drugs, such as levofloxacin 
(750 mg, daily) and meropenem (1 g, 3 times a day), as 
well as antiviral drugs, such as oseltamivir (75 mg, Twice 
daily) and hydroxychloroquine (200 mg, twice daily). The 
patient was discharged from the hospital after 11 days 
with complete recovery (Figure 1).
Figure 1: Chest X-Ray imaging from Patient 1 (Left) and Patient four 
(Right)
Case 2
The patient was a 51-year-old housewife who 
was referred to the hospital with her daughter with 
complaint of dry cough and shortness of breath, sore 
throat, and periodic fever (39.5°C) and chills. On further 
examination, the patient also reported symptoms, such 
as chest pain, headache, and diarrhea. The patient did 
not mention any previous history of the disease. She 
had attended a ceremony about 2 weeks ago and had 
contact with a person whose COVID-19 RT-PCR test was 
positive. The patient symptoms were treated by antibiotic 
therapy and the antiviral drugs, such as oseltamivir 
(75 mg, twice daily) and hydroxychloroquine (200 mg, 
twice daily). On the physical examination, the patient 
was observed with dehydration, myalgia, and fever. The 
vital signs of the patient were BP =135/80, T = 39.5, 
SPO2 = 86%, HR =83, and RR =16. Oxygen therapy 
was performed immediately with mask (8 L/min). CXR 
and CT-scan findings indicated bilateral pneumonia. The 
patient was discharged after 12 days of care.
Case 3
The patient was a 68-year-old female, with 
symptoms of fever (39.4°C), cough, sore throat, and 
shortness of breath, who had been hospitalized for 
several days, and had been referred to Razi Hospital 
through a pre-hospital emergency medical service. 
In the initial examination, the patient had temporary 
symptoms of anorexia, nausea, dehydration, and chest 
pain. She had no previous history of the disease. She 
did not have a history of travel to China or contact with 
a positive COVID-19 patient. The patient participated 
in school ceremony for 14 days before admission and 
hospitalization. The patient treatments were symptomatic 
and included with antibiotics, such as levofloxacin 
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(750 mg, daily) and meropenem (1 g, 3 times a day), as 
well as antiviral drugs, such as oseltamivir (75 mg, twice 
daily) and hydroxychloroquine (200 mg, twice daily). 
The vital signs of the patient were BP =100/60, T = 37.2, 
SPO2 = 75%, HR =88, and RR =18. Oxygen therapy 
was performed immediately with mask (8 L/min) to 
improve the patient’s condition. CXR and chest CT-scan 
imaging findings have indicated a unilateral pneumonia. 
Laboratory findings showed the high levels of erythrocyte 
sedimentation rate (ESR) and negative C-reactive protein 
(CRP). In laboratory tests, the patient had leukocytosis 
and hypernatremia. She was discharged after 14 days of 
care and improvement of clinical symptoms.
Case 4
The patient was a 40 years old, a teacher, 
who was referred to the emergency department with 
complaints of cough, sore throat, shortness of breath, 
nausea, vomiting, and diarrhea. On initial examination, 
the patient had symptoms of fatigue, anorexia, fever 
(39°C), chills, and dehydration. There was no previous 
underlying disease. Due to exacerbation of condition 
and SPO2 = 29.9%, the patient was transferred to the 
intensive care unit (ICU) and subjected to intubation and 
underwent mechanical ventilation with synchronized 
intermittent mandatory ventilation mode. The patient 
has had a history of attending school for the past 
14 days. The patient’s treatment was symptomatic, 
using antibiotic and antiviral drugs. CXR and chest 
CT-scan results indicated a bilateral pneumonia. In 
the study of the patient’s laboratory findings, creatine 
phosphokinase, creatine phosphokinase-MB, and ESR 
showed an increase of 271, 103, and 64, respectively. 
The patient died after 4 days of intubation in the ICU 
due to severe pulmonary involvement and respiratory 
distress syndrome (Figure 1).
Case 5
The patient was a 65-year-old, retired, who 
was referred to emergency department of the hospital 
with complaints of shortness of breath, fatigue, and 
abdominal pain. In the skin turgor examination, patient 
had dehydration. The patient had no fever (T = 37.5), but 
gastrointestinal symptoms such as anorexia, nausea, 
vomiting, and diarrhea were observed for 3 days. The 
patient has not been in any meeting for the past 14 days. 
He had a history of diabetes and hypertension. Initially, 
the patient received oxygen (6 L/min), levofloxacin 
(750 mg, daily), as well as oseltamivir (75 mg, twice 
daily), and hydroxychloroquine (200 mg, twice daily). 
CXR and chest CT-scan imaging results showed a 
unilateral pneumonia. Laboratory results were as follows: 
LDH =952 (elevated), creatine phosphokinase=54 
(elevated), and BS =438. After 11 days of symptomatic 
care, antibiotics and antiviral therapy, the patient was 
discharged with improved clinical symptoms.
Case 6
The patient was 58-year-old man who has 
been referred to emergency department by ambulance. 
The patient’s chief complaints were high fever (39.5°C), 
chills, dry cough, sore throat, and shortness of breath. 
On initial examination, the patient was suffering from 
chest pain, fatigue, and loss of appetite. He had been 
smoking a pack of cigarettes daily for the past 20 years. 
He had no history of underlying disease. He did not have 
a history of travel to China or contact with a positive 
COVID-19 patient. Initially, oxygen therapy (9 L/min) 
was performed for symptomatic treatment, but on the 
2nd day of hospitalization after reduction in arterial blood 
oxygen level (O2sat =72%), the patient was intubated 
and treated with bi-level positive airway pressure 
(BiPAP). Antibiotic therapy with levofloxacin (750 mg, 
daily), as well as antiviral therapy with oseltamivir 
(75 mg, twice daily) and hydroxychloroquine (200 mg, 
twice daily) were administered to the patient. CXR and 
chest CT-scan results were also evaluated and bilateral 
pneumonia was observed. In the last follow-up after 
19 days, he was hospitalized and received treatment.
Case 7
The patient was a 65-year-old man, who 
was presented to the hospital complaining of cough, 
sore throat, fever, chills, and night sweats. On further 
examination, the patient’s appetite has decreased 
and he was suffering from fatigue, headache, and 
dehydration. The patient’s initial temperature was 
38°C, which peaked at 39.2°C after 4 days. From day 
5, a decreasing trend was found and finally reached 
at 37.8°C on day 10. The patient had a history of 
diabetes. On the other hand, he had traveled to Tehran 
in the past 14 days. The patient receives antibiotic 
and antiviral treatments with levofloxacin (750 mg, 
daily) and oseltamivir (75 mg, twice daily). CXR and 
chest CT-scan imaging results were also reviewed and 
bilateral pneumonia was observed. The patient’s LDH 
level was high (821 U/L). The patient is currently in 
hospital and undergoing treatment (Figure 2).
Additional results
The mean age of the patients was 60.85 years 
ranged from 40 to 79 years old. Four of the patients 
were male and three were female. All patients were 
residents of Rasht and were indirectly exposed and 
affected due to the widespread prevalence of this 
disease in this city. None of the patients had a close 
relationship with the history of traveling to China or with 
people who had traveled there. The patients’ symptoms 
included: Poor appetite (seven cases), dehydration 
(seven cases), cough (six cases), dyspnea (six cases), 
fatigue (six cases), fever (five cases), myalgia (five 
cases), chills (five cases), feeling febrile (five cases), 
sore throat (five cases), nausea (five cases), vomiting 
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(four cases), headache (three cases), chest pain 
(three cases), diarrhea (three cases), and wheezing 
(one case). Body temperature higher than 38°C was 
observed in five patients with a mean of 39.32°C (from 
39°C to 39.5°C). The results of chest radiography 
revealed four cases with bilateral pneumonia, two cases 
of unilateral pneumonia with right lung involvement, 
and one case of unilateral pneumonia with left lung 
involvement. Furthermore, unilateral multiple mottling 
and ground glass opacity were observed in three 
cases. All patients received antibiotics and received 
symptomatic treatment, and three were intubated 
due to low O2 saturation. For all patients, medications 
such as: Oseltamivir capsule (75 mg, twice daily), 
hydroxychloroquine tablets (200 mg, twice daily), 
diphenhydramine (10 ml, four times a day before 
meals), intravenous ranitidine (25 mg/ml, twice daily), 
acetaminophen tablets in case of pain, ondansetron 
tablets in case of nausea, salbutamol, and ipratropium 
spray (two puffs in case of shortness of breath; 4 times 
a day), ceftriaxone (1 g, twice daily), meropenem (1 g, 
twice daily), vancomycin (1 g, twice daily), and oxygen 
therapy (in case of shortness of breath). A total of four 
patients responded appropriately to treatments and 
were discharged, two patients were still hospitalized and 
one patient expired. More detailed information is shown 
in Table 1. Furthermore, the patients’ all laboratory data 
are presented in Table 2.
Discussion
Coronavirus is one of the major pathogens 
causing respiratory infections in humans. Two types 
of this pathogen including SARS-CoV and MERS-CoV 
are highly pathogenic, causing severe respiratory 
syndrome in humans [1]. Initial and major outbreaks 
of SARS-CoV between 2002 and 2003 leads to a total 
of 8422 confirmed infected cases in 29 countries [14]. 
MERS-CoV appeared in 2012 in Asia and the Middle 
East [15]. The SARS-CoV mortality rate was more than 
10% and MERS-CoV was more than 35% [16].
This study was conducted in Rasht, the capital 
city of Guilan Province, north of Iran, due to the high 
prevalence of the disease and the establishment of an 
epidemic area. None of patients in this study had a history 
of traveling to China, or contacts with people who came 
from China in the past 2 weeks. It seems that these 
patients had contact with suspected COVID19 patients, 
which was similar to Li et al. [3], but in the study of Chen 
et al., all patients were from individuals associated 
with the Chinese seafood market [1], which may be 
attributed to the study’s location.
The most common clinical manifestations of 
patients with COVID 19 infected pneumonia in this 
study were poor appetite and dehydration (all patients), 
cough, sore throat, dyspnea, fatigue, fever higher than 
38°C, chills, and myalgia, respectively. However, a 
study by Chen et al. reported that fever, cough, and 
dyspnea were the most common symptoms in these 
patients [1]. Ethnicity and having underlying disease 
are the possible reasons for this difference. In a similar 
study, Wei Xu et al., in Wuhan, China, reported that 
the most common clinical symptoms of the patients 
were fatigue, myalgia, headache, diarrhea, and 
vertigo, respectively [3], [17]. According to the results 
of our study, about half of patients had underlying 
diseases, such as hypertension, diabetes mellitus, 
and cardiovascular disease. Badawi et al. reported 
that about half of MERS-CoV patients had underlying 
diseases, such as diabetes mellitus, hypertension, and 
heart disease [18]. Furthermore, in this study, similar 
to other studies, the majority of patients had older age, 
people with underlying diseases and reduced immune 
systems were more likely to be affected [1], [19].
According to the results of our study, unlike 
the study by Chen et al., the levels of lymphocytes 
and white blood cells were within the normal range [1]. 
Moreover, in our investigation, CRP were negative in 
most cases (71.42%), which was consistent with the 
study by Wang et al. study [20]. It has been previously 
reported a 75–93% of elevated levels of CRP in COVID-
19 patients [1], [13], [21], [22], [23]. This might be 
related to underlying diseases and other characteristics 
of infected patients. There has been shown an inverse 
association between the underlying diseases such as 
diabetes mellitus, hypertension and kidney and liver 
disease and higher CRP level in patients with acute or 
chronic illnesses [2], [24], [25]. In our study, the serum 
levels of other biomarkers such as LDH and ESR 
were increased significantly in COVID 19 patients, that 
is in line with study of Chen et al. (85% increase in 
ESR) [1]. The previous studies showed the increases 
Figure 2: Transversal chest CT-scan and Chest X-Ray imaging from 
Patient seven
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Table 1: Clinical features among COVID-19 infected in Rasht, Iran
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Basic information
Admission date (2020) March 5 March 6 March 6 February 28 March 5 February 27 March 2
Age (years) 79 51 68 40 65 58 65
Sex Female Female Female Male Male Male Male
Occupation Housewife Housewife Housewife Teacher Retired farmer Freelance
Epidemiological history
Contact with index case directly Unknown Yes Unknown Unknown Unknown Unknown Unknown
Current smoking No No No No No Yes No
Hypertension Yes No No No Yes No No
Diabetes No No No No Yes No Yes
Cardiovascular disease Yes No No No No No No
Coronary artery disease Yes No No No No No No
Clinical characteristics
Peak of fever (°C) Afebrile 39.5 39.4 39 afebrile 39.5 39.2
Duration of fever (days) -- 7 2 6 -- 2 3
Cough Yes Yes Yes Yes No Yes Yes
Sore throat No Yes Yes Yes No Yes Yes
Dyspnea No Yes Yes Yes Yes Yes Yes
wheezing No No No No Yes No No
Diarrhea No Yes No Yes Yes No No
Nausea No Yes Yes Yes Yes Yes No
Vomit No No No Yes Yes Yes Yes
Abdominal pain No No No No Yes No Yes
Poor appetite Yes Yes Yes Yes Yes Yes Yes
Fatigue Yes No Yes Yes Yes Yes Yes
Dehydration Yes Yes Yes Yes Yes Yes Yes
Myalgia No Yes Yes Yes No Yes Yes
Feeling fever No Yes Yes Yes No Yes Yes
Chills No Yes Yes Yes No Yes Yes
Headache No Yes No No No Yes Yes
Chest pain No Yes No No No Yes Yes
Treatment
Symptomatic treatment Yes Yes Yes Yes Yes Yes Yes
Antibiotic Yes Yes Yes Yes Yes Yes Yes
Antivirus Yes Yes Yes Yes Yes Yes Yes
Oxygen therapy No Yes Yes Yes Yes Yes Yes
Intubation No No No Yes No Yes Yes
Chest X-ray and CT-scan findings
Bilateral or unilateral pneumonia Unilateral right lung Bilateral Unilateral left lung Bilateral Unilateral right lung Bilateral Bilateral
Multiple mottling and GGO No No No Yes No Yes Yes
Affected lobe 2 3 2 5 2 4 4
Clinical outcome Discharged Discharged Discharged Died Discharged Remained in hospital Remained in hospital
Table 2: Laboratory values of all patients
White blood cell count (×10⁹ /L); (normal range 4–11) 8.7 3.3↓ 12.7↑ 6 7.1 7.7 6.9
Red blood cell count 3.13 3.76 4.4 4.15 4.89 5.53 4.77
Hemoglobin (g/dL) 9.1 10.7 11.3 11.9 14.9 14.7 13.8
Hematocrit (%) 29 31.7 36.9 35.3 43.2 44.6 44.6
Mean corpuscular volume (F.L) 92.7 84.3 83.9 85.1 88.3 80.7 93.5
Neutrophil count (%) NA NA NA NA 70 NA NA
Lymphocyte count (%) NA NA NA NA 27 NA NA
Platelet count (×10⁹ /L) 330 249 362 236 247 258 203
Erythrocyte sedimentation rate 1 h (mm/h) NA 114↑ 92↑ 64↑ NA NA NA
Blood Sugar (mg/dL) 141 ↑ 186 NA 109 438 162 349
BUN (mg/dL) 28↑ 10 21↑ 20 36↑ 28↑ 13
Creatinine (mg/dL) 1.3 0.9 1.2 1.3 1.2 1.1 0.9
eGFR (U/L) 40.85 ≥60 44.72 ≥60 ≥60 ≥60 ≥60
Aspartate aminotransferase (U/L) 16 28 NA NA 27 NA 42↑
Alanine aminotransferase (U/L) 18 30 NA NA 30 NA 31
Alkaline phosphatase (U/L) 336↑ 226 NA NA 253 NA 177
Lactate dehydrogenase (U/L) 382 1048↑ 1237↑ NA 952↑ NA 821↑
Creatine phosphokinase (U/L) 64 168 296↑ 1788↑ 271↑ 193 NA
Creatine phosphokinase-MB (U/L) 21 39↑ NA 54↑ 103↑ 135↑ NA
Ca (mg/dL) 9.2 8.2↓ NA NA 9 NA 8.5↓
Phosphorus (mg/dL) 4.4 2.0↓ NA NA 3 NA 3.1
Na (mEq/L) 137 135 131↓ 134↓ 130↓ 130↓ 134↓
K (mEq/L) 4.2 3.7 3.7 4.7 4.3 5 4
C-reactive protein (mg/L) 3 Negative Negative Negative Negative Negative 1
Arterial blood gas
PH NA NA 7.361 7.36 NA NA NA
Pco2 (mmHg) NA NA 32.5 44 NA NA NA
Po2 (mmHg) NA NA 50.2 20.4 NA NA NA
Hco3 (mEq/L) NA NA 18 24.3 NA NA NA
O2 Sat (%); (normal range 95–100) NA NA 82.8↓ 29.9↓ NA NA NA
BE (mmol/L) NA NA −6.2↓ −1.2 NA NA NA
BB (mmol/L) NA NA 41.7 46.7 NA NA NA
BUN: Blood urea nitrogen, eGFR: Estimated glomerular filtration rate, BE: Base excess, BB: Buffer base.
approximately 69–92% in serum LDH level in patients 
with COVID 19 patients, which was consistent with our 
findings [2], [22]. But unlike to our study, in the Xu et al. 
study, LDH levels increased in 27% of patients [17].
According to the results of our study, the results 
of chest radiography and CT scan, in most patients 
showed bilateral pneumonia that was consistent with 
the results of studies by Liu et al., Chen et al., and Chang 
et al. [1], [26], [27]. In another study, almost all patients 
had bilateral pneumonia [3], which may be attributed to 
the deterioration of their patients’ conditions.
In our study, supportive treatments such as 
oxygen therapy, antibiotics, and antivirals medications 
were used for all patients. Antibiotic and antiviral 
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medications such as ceftriaxone, meropenem, 
vancomycin, oseltamivir, and hydroxychloroquine were 
used for patients, if needed. The previous studies have 
also used these drugs [1], [26] However, it has been 
shown that despite using these medications, they were 
effective only in the treatment of SARS-CoV and MERS-
CoV [28] and reported that there is no strong evidence 
for the effective drug treatment of COVID19 [26]. 
However, the majority of our patients received these 
medications with a positive response.
Conclusion
Patients with COVID-19 associated pneumonia 
can be treated by evaluating and implementing 
appropriate therapeutic management. However, at 
the moment the disease progression for patients with 
COVID-19 cannot be accurately predicted. Prompt 
diagnosis, effective treatment, and use of chest 
CT-scan are essential for appropriate management and 
surveillance for disease features.
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